Iqvia Holdings Inc.
IQVIA Reports Q1 2024 Financial Results
Summary
IQVIA Holdings Inc. reported its financial results for the first quarter of 2024, showing a revenue of $3,737 million, GAAP net income of $288 million, and Adjusted EBITDA of $862 million. The company reaffirmed its full-year guidance, expecting revenue growth of 2.3 to 3.9 percent on a reported basis and Adjusted EBITDA growth of 3.7 to 6.5 percent. IQVIA also announced a book-to-bill ratio of 1.23x for the quarter, indicating strong demand and bookings.
Profitelligence Alerts
Get alerts for IQV
Be first to know when Iqvia Holdings Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Official SEC Documents
Advertisement